Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

PURPOSE: To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors. METHODS: Characteristics and survival of patients treated with afatinib after resistance to erloti...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Wekken, A. J., Kuiper, J. L., Saber, A., Terpstra, M. M., Wei, J., Hiltermann, T. J. N., Thunnissen, E., Heideman, D. A. M., Timens, W., Schuuring, E., Kok, K., Smit, E. F., van den Berg, A., Groen, H. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576694/
https://www.ncbi.nlm.nih.gov/pubmed/28854272
http://dx.doi.org/10.1371/journal.pone.0182885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576694/
https://www.ncbi.nlm.nih.gov/pubmed/28854272
http://dx.doi.org/10.1371/journal.pone.0182885

Ejemplares similares